Advertisement

Clinical Scenario: Management of Side Effects from Bacillus Calmette-Guérin Bladder Instillation

68-Year-old man previously treated years ago with BCG who has a high-grade Ta tumor with significant lower urinary tract symptoms after receiving his third dose of a planned 6-week BCG induction course
  • Donald L. Lamm
  • Nilay M. GandhiEmail author
Chapter

Abstract

Bacillus Calmette-Guérin (BCG) immunotherapy currently remains the most effective treatment for intermediate- and high-risk non-muscle-invasive bladder cancer, but has side effects that range from bothersome to life-threatening. Side effects are best prevented by reducing the dose of BCG, postponing the treatment, and prescribing a fluoroquinolone antibiotic 6 and 18 h after instillation for patients who begin to have increasing symptoms. Side effects are caused by both BCG infection and BCG hypersensitivity. Serious, life-threatening reactions require treatment with triple antitubercular antibiotics and steroids. Moderate reactions can be treated with fluoroquinolone and isoniazid, but with established infection it often takes many weeks for symptoms to improve and 3 or more months of treatment are required. Infectious complications of BCG may be avoided in BCG-intolerant patients by using heat-killed BCG.

Keywords

Bladder cancer BCG immunotherapy Complications Antitubercular antibiotics Sepsis 

References

  1. 1.
    Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int. 2013;112:288–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Koukol SC, DeHaven J, Riggs DR, Lamm DL. Drug therapy of bacillus Calmette-Guérin sepsis. Urol Res. 1995;22(6):273.CrossRefGoogle Scholar
  3. 3.
    Lamm DL, Reichert FD, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol. 1982;128(5):1104–8.PubMedGoogle Scholar
  4. 4.
    Palou J, Laguna P, Millan-Rodrıguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodrıguez J. Control group and maintenance treatment with bacillus Calmette-Guérin for carcinoma in situ and/or high grade bladder tumors. J Urol. 2001;165:1488–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Weir RE, Gorak-Stolinska P, Floyd S, Lalor MK, Stenson S, Branson K, Blitz R, Anne Ben-Smith B, Fine PEM, Dockrell HM. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis. 2008;8:9.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    DeBoer EC, DeJong WH, Steerenberg PA, Aarden LA, Tetteroo E, DeGroot ER, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34:306–12.CrossRefGoogle Scholar
  7. 7.
    Colombel M, Saint F, Chopin D, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–73.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am. 1992;19:565–72.PubMedGoogle Scholar
  10. 10.
    Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace Jr RJ. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005;172(2):250–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301(22):2362–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, Clawson S, Barlow T, Parmar MK, Griffiths GO. National Cancer Research Institute Bladder Clinical Studies Group: a randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol. 2007;178(3):807–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See W. Loss of BCG viability adversely affects the direct response of urothelial carcinoma cells to BCG exposure. J Urol. 2013;191:823–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Lamm DL, Harris SC, Gittes RF. Bacillus Calmette-Guérin and Dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. Invest Urol. 1977;14:369.PubMedGoogle Scholar
  15. 15.
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guérin determine the succeeding Th1 response. J Urol. 2003;170(5):2004–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Lamm DL, Gandhi NM, Iverson T, et al. Clinical experience with heat-inactivated bacillus Calmette-Guérin (BCG) immunotherapy. J Urol. 2013;4:733.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.BCG OncologyUniversity of ArizonaPhoenixUSA
  2. 2.James Buchanan Brady Urological InstituteJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations